Medtronic (MDT) 8-K on Q2 FY2026 Results Press Release

Q: Which financial period does this Medtronic (MDT) 8-K relate to?

The report relates to Medtronic’s second quarter of fiscal year 2026, for which financial results are described in the press release attached as Exhibit 99.1.

Q: What exhibits are included with this Medtronic (MDT) 8-K filing?

The filing includes Exhibit 99.1, which is the press release dated November 18, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded in the Inline XBRL document.

Q: Who signed this Medtronic (MDT) Form 8-K?

The Form 8-K was signed on behalf of Medtronic plc by Thierry Piéton, Executive Vice President and Chief Financial Officer, who serves as the principal financial officer.

Q: Where is Medtronic plc incorporated and headquartered?

Medtronic plc is organized under the laws of Ireland, with its principal executive offices located at Building Two, Parkmore Business Park West, Galway, Ireland.

Q: Which Medtronic (MDT) securities are listed on the New York Stock Exchange?

Medtronic lists its ordinary shares (MDT) and multiple series of senior notes on the New York Stock Exchange, with maturities from 2027 through 2053.

Medtronic plc filed a current report to announce that it released its financial results for the second quarter of its fiscal year 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Medtronic plc filed a current report to announce that it released its financial results for the second quarter of its fiscal year 2026. On November 18, 2025, the company issued a press release with these results, which is included as Exhibit 99.1. The report also confirms Medtronic’s status as an Irish public limited company and lists its ordinary shares and various series of senior notes, with maturities ranging from 2027 to 2053, as being listed on the New York Stock Exchange.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medtronic (MDT) announce in this Form 8-K?

Medtronic plc reported that on November 18, 2025, it issued a press release announcing its second quarter fiscal year 2026 financial results, furnished as Exhibit 99.1.

Which financial period does this Medtronic (MDT) 8-K relate to?

The report relates to Medtronic’s second quarter of fiscal year 2026, for which financial results are described in the press release attached as Exhibit 99.1.

What exhibits are included with this Medtronic (MDT) 8-K filing?

The filing includes Exhibit 99.1, which is the press release dated November 18, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded in the Inline XBRL document.

Who signed this Medtronic (MDT) Form 8-K?

The Form 8-K was signed on behalf of Medtronic plc by Thierry Piéton, Executive Vice President and Chief Financial Officer, who serves as the principal financial officer.

Where is Medtronic plc incorporated and headquartered?

Medtronic plc is organized under the laws of Ireland, with its principal executive offices located at Building Two, Parkmore Business Park West, Galway, Ireland.

Which Medtronic (MDT) securities are listed on the New York Stock Exchange?

Medtronic lists its ordinary shares (MDT) and multiple series of senior notes on the New York Stock Exchange, with maturities from 2027 through 2053.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/18/2025 - 06:47 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

FORM 8-K

_____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2025

_____________________________

Medtronic plc

(Exact name of Registrant as Specified in its Charter)

_____________________________

Ireland

1-36820

98-1183488

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Building Two

Parkmore Business Park West

Galway, Ireland

(Address of principal executive offices) (Zip Code)

+353 1 438-1700

(Registrant’s telephone number, including area code)



Not Applicable
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Ordinary shares, par value $0.0001 per share	MDT	New York Stock Exchange
1.125% Senior Notes due 2027	MDT/27	New York Stock Exchange
0.375% Senior Notes due 2028	MDT/28	New York Stock Exchange
3.000% Senior Notes due 2028	MDT/28A	New York Stock Exchange
3.650% Senior Notes due 2029	MDT/29	New York Stock Exchange
2.950% Senior Notes due 2030	MDT/30	New York Stock Exchange
1.625% Senior Notes due 2031	MDT/31	New York Stock Exchange
1.000% Senior Notes due 2031	MDT/31A	New York Stock Exchange
3.125% Senior Notes due 2031	MDT/31B	New York Stock Exchange
0.750% Senior Notes due 2032	MDT/32	New York Stock Exchange
3.375% Senior Notes due 2034	MDT/34	New York Stock Exchange
3.875% Senior Notes due 2036	MDT/36	New York Stock Exchange
2.250% Senior Notes due 2039	MDT/39A	New York Stock Exchange
1.500% Senior Notes due 2039	MDT/39B	New York Stock Exchange
1.375% Senior Notes due 2040	MDT/40A	New York Stock Exchange
4.150% Senior Notes due 2043	MDT/43A	New York Stock Exchange
4.200% Senior Notes due 2045	MDT/45	New York Stock Exchange
1.750% Senior Notes due 2049	MDT/49	New York Stock Exchange
1.625% Senior Notes due 2050	MDT/50	New York Stock Exchange
4.150% Senior Notes due 2053	MDT/53	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02.			Results of Operations and Financial Condition

On November 18, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.


Item 9.01.			Exhibits.

(d) List of Exhibits


Exhibit Number						Description

99.1						Press release of Medtronic plc, dated November 18, 2025
104						Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

/s/ Thierry Piéton

Date: November 18, 2025

Thierry Piéton

Executive Vice President and Chief Financial Officer (Principal Financial Officer)

EXHIBIT INDEX


Exhibit Number						Description

99.1						Press release of Medtronic plc, dated November 18, 2025
104						Cover Page Interactive Data File (embedded with the Inline XBRL document).

Source: View Original Filing on SEC EDGAR

Medtronic (MDT) 8-K on Q2 FY2026 Results Press Release

Rhea-AI Filing Summary

Positive

Negative

8-K Event Classification

FAQ

What did Medtronic (MDT) announce in this Form 8-K?

Which financial period does this Medtronic (MDT) 8-K relate to?

What exhibits are included with this Medtronic (MDT) 8-K filing?

Who signed this Medtronic (MDT) Form 8-K?

Where is Medtronic plc incorporated and headquartered?

Which Medtronic (MDT) securities are listed on the New York Stock Exchange?

Keep reading

More on MDT

Trending in the feed